Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C14H12FN3O2 |
| Molecular Weight | 273.2624 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=O)N\N=C\C1=CC=C(OC2=CC=C(F)C=C2)C=C1
InChI
InChIKey=MHUUDVZSPFRUSK-RQZCQDPDSA-N
InChI=1S/C14H12FN3O2/c15-11-3-7-13(8-4-11)20-12-5-1-10(2-6-12)9-17-18-14(16)19/h1-9H,(H3,16,18,19)/b17-9+
CO-102862, also known as V102862, is a potent, broad-spectrum state-dependent blocker of mammalian voltage-gated sodium channels. A key feature of the mechanism of inhibition is that
V102862 has up to 80-fold higher affinity for inactivated Na
channels as compared to channels in resting states. V102862 is an orally active anticonvulsant with robust activity in a variety of rodent models of epilepsy.
Originator
Approval Year
Sample Use Guides
In an experimental rat model of peripheral neuropathic pain, CO-102862 demonstrated marked antiallodynic effects, producing dose-dependent reversals of tactile sensitivity at oral doses ≥2.5 mg/kg (plasma levels of 480 ng/ml) in a 10% Tween 80 formulation.
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
0KN11H90GF
Created by
admin on Sat Dec 16 09:23:14 GMT 2023 , Edited by admin on Sat Dec 16 09:23:14 GMT 2023
|
PRIMARY | |||
|
DTXSID70171079
Created by
admin on Sat Dec 16 09:23:14 GMT 2023 , Edited by admin on Sat Dec 16 09:23:14 GMT 2023
|
PRIMARY | |||
|
9816959
Created by
admin on Sat Dec 16 09:23:14 GMT 2023 , Edited by admin on Sat Dec 16 09:23:14 GMT 2023
|
PRIMARY | |||
|
181144-66-1
Created by
admin on Sat Dec 16 09:23:14 GMT 2023 , Edited by admin on Sat Dec 16 09:23:14 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
